Drug Approval | August 16, 2023
Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Shivalik Rasayan Limited has issued LOA to Medicamen Biotech to use its DMF grade Bortezomib API for formulation of Bortezomib injection 3.5mg/ vial
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
Subscribe To Our Newsletter & Stay Updated
